[The antithrombotic treatment and prevention of recurrence with acetylsalicylic acid in myocardial infarct].
A comparison of the therapy, especially of the long-term recidivation prophylaxis of the myocardial infarction with acetyl salicylic acid and anticoagulants, on the basis of 314 observations allows of the following opinions: By means of the thrombocyte aggregation inhibitor acetyl salicylic acid an antithrombotic therapy and recidivation prophylaxis of good value can be performed. The application of acetyl salicylic acid is, concerning the course of the disease after the onset of the infarction and the frequency of recidivation, adequate to the treatment with classical anticoagulants. The practical performance of the long-term therapy with acetyl salicylic acid is significantly simplified for physician and patient compared with the application of anticoagulants. The daily dose lies uniformly at 1.5 g. There is no fear of acute haemorrhagic complications. As control only the occasional establishment of the Hb-value as well as of the time of haemorrhage is indicated. The only, however, very decisive disadvantage of the acetyl salicylic acid, the bad compatibility for the stomach, is certainly not abolished with the new drug "Micristin", but much diminished.
D000818:Animals; D000925:Anticoagulants / Q000627:therapeutic use; D001241:Aspirin / Q000009:adverse effects / Q000627:therapeutic use*; D004285:Dogs; D004342:Drug Hypersensitivity; D006471:Gastrointestinal Hemorrhage / Q000139:chemically induced; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy / Q000517:prevention & control*; D011817:Rabbits; D012008:Recurrence; D013927:Thrombosis / Q000517:prevention & control; D014581:Urticaria / Q000139:chemically induced
D000925:Anticoagulants; D001241:Aspirin
Die antithrombotische Behandlung und Rezidivprophylaxe des Myokardinfarktes mit Azetylsalizylsäure